Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 29OTHER 13NIH 4NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 38Magnetic Resonance Spectroscopy 33Biopsy 16Radiation 15Cyclophosphamide 15Radiotherapy 14Vincristine 12Leucovorin 11Dexamethasone 11Carboplatin 11Etoposide 10Cisplatin 10Cytarabine 9Calcium Dobesilate 9dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8Fluorouracil 8X-Rays 7Standard of Care 7Radiotherapy, Intensity-Modulated 7Practice Guidelines as Topic 7Platinum 7Doxorubicin 71,2-diaminocyclohexaneplatinum II citrate 7merphos 6dehydroftorafur 6Taxes 6Methotrexate 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Injections × 30 days × Clear all
NCT07085728 2026-05-15

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
74 enrolled
Plasma cell

Multiple Myeloma

NCT04293562 2026-05-05

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Children's Oncology Group

Phase 3 Recruiting
1,186 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡